Decreasing Tumor Growth and Angiogenesis by Inhibition of Coagulation

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Coagulation proteins are known to promote angiogenesis and tumor growth.
• Traditional anticoagulants like warfarin and heparins carry bleeding risks, limiting their therapeutic potential in cancer.
• Heparanase protein, a cofactor for tissue factor (TF), enhances coagulation and tumor progression through non-hemostatic effects.

Purpose of the Study:

• To explore the potential of targeting the coagulation system for cancer treatment.
• To investigate heparanase as a therapeutic target for reducing tumor growth and metastasis.
• To identify anticoagulant strategies with a low bleeding tendency.

Main Methods:

• Review of existing data on coagulation proteins and cancer.
• Analysis of heparanase function in tumor biology and coagulation.
• Evaluation of heparin mimetics and TF pathway inhibitor 2-derived heparanase inhibitors.

Main Results:

• Heparanase enhances coagulation activation and possesses non-hemostatic pro-tumorigenic effects.
• Heparin mimetics and TF pathway inhibitor 2 derivatives inhibit heparanase.
• These heparanase inhibitors exhibit a low bleeding tendency.

Conclusions:

• Targeting heparanase activity presents a promising strategy for developing novel antitumor drugs.
• Inhibiting heparanase offers an alternative to traditional anticoagulants with reduced bleeding risk.
• Interference with heparanase offers a dual benefit of inhibiting coagulation and tumor growth.